Alnylam Pharmaceuticals - ALNY Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $247.40
Forecasted Upside: 42.31%
Number of Analysts: 21
Breakdown:
0 Sell Ratings
5 Hold Ratings
16 Buy Ratings
0 Strong Buy Ratings

^$173.85 As of 09/21/2023 01:00 AM ET

▼ -1.67 (-0.95%)

1 month | 3 months | 12 months

Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

^$247.40

▲ +42.31% Upside Potential

This price target is based on 21 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $247.40, with a high forecast of $405.00 and a low forecast of $143.00. The average price target represents a 42.31% upside from the last price of $173.85.

Current Consensus is Moderate Buy

The current consensus among 21 polled investment analysts is to moderate buy stock in Alnylam Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/30/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

6/28/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

9/26/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/25/2022

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/25/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

6/23/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

8/22/2023

0 strong buy ratings
16 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

9/21/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/18/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$405.00	Low
9/14/2023	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$240.00	Low
9/14/2023	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$190.00	Low
9/12/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$240.00	Low
9/12/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$270.00	Low
8/28/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$270.00	Low
8/18/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$270.00	Low
8/16/2023	Cantor Fitzgerald	Reiterated Rating	Neutral ➝ Neutral	$190.00	Low
8/8/2023	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$250.00	Low
8/7/2023	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$405.00	Low
8/4/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$210.00	Low
8/4/2023	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$270.00	Low
8/4/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$240.00	Low
8/4/2023	Citigroup	Boost Target	Buy ➝ Buy	$265.00 ➝ $266.00	Low
7/26/2023	Sanford C. Bernstein	Lower Target		$247.00 ➝ $233.00	Low
7/25/2023	William Blair	Reiterated Rating	Outperform		Low
7/25/2023	Royal Bank of Canada	Lower Target	Outperform	$275.00 ➝ $270.00	Low
7/25/2023	HC Wainwright	Lower Target	Buy	$415.00 ➝ $405.00	Low
5/5/2023	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$200.00 ➝ $250.00	Low
4/26/2023	Sumitomo Mitsui Financial Group	Initiated Coverage	Neutral	$220.00	Low
4/4/2023	Morgan Stanley	Boost Target	Equal Weight	$205.00 ➝ $210.00	Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Outperform	$243.00	Low
3/3/2023	JPMorgan Chase & Co.	Lower Target	Neutral	$200.00 ➝ $196.00	Low
3/3/2023	HC Wainwright	Reiterated Rating	Buy	$415.00	Low
2/24/2023	Needham & Company LLC	Reiterated Rating	Buy	$240.00	Low
2/24/2023	Chardan Capital	Reiterated Rating	Buy	$250.00	Low
2/24/2023	Oppenheimer	Lower Target	Outperform	$256.00 ➝ $249.00	N/A
2/24/2023	Morgan Stanley	Lower Target	Equal Weight	$210.00 ➝ $205.00	N/A
2/24/2023	Canaccord Genuity Group	Lower Target	Buy	$310.00 ➝ $291.00	Low
2/24/2023	Citigroup	Lower Target	Buy	$270.00 ➝ $265.00	Low
2/21/2023	EF Hutton Acquisition Co. I	Initiated Coverage	Buy	$304.00	Low
1/23/2023	SVB Leerink	Lower Target	Market Perform	$144.00 ➝ $143.00	Low
1/18/2023	Canaccord Genuity Group	Initiated Coverage	Buy	$310.00	Low
12/16/2022	Piper Sandler	Boost Target	Overweight	$226.00 ➝ $253.00	Low
11/7/2022	SVB Leerink	Boost Target	Market Perform	$142.00 ➝ $145.00	Low
11/2/2022	HC Wainwright	Lower Target	Buy	$430.00 ➝ $415.00	N/A
10/28/2022	Barclays	Lower Target	Overweight	$240.00 ➝ $236.00	Low
10/28/2022	Morgan Stanley	Lower Target	Equal Weight	$220.00 ➝ $210.00	Low
10/28/2022	The Goldman Sachs Group	Boost Target	Buy	$239.00 ➝ $270.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$204.00 ➝ $200.00	Low
10/13/2022	Morgan Stanley	Lower Target	Equal Weight	$222.00 ➝ $220.00	Low
10/3/2022	Jefferies Financial Group	Boost Target	Buy	$218.00 ➝ $232.00	Low
9/20/2022	Royal Bank of Canada	Boost Target	Outperform	$225.00 ➝ $250.00	Low
9/9/2022	Morgan Stanley	Reiterated Rating	Equal Weight	$225.00 ➝ $222.00	Low
9/9/2022	BMO Capital Markets	Boost Target	Market Perform	$192.00 ➝ $200.00	Low
9/9/2022	Oppenheimer	Boost Target	Outperform	$170.00 ➝ $256.00	Low
8/9/2022	Evercore ISI	Boost Target		$252.00	N/A
8/4/2022	BMO Capital Markets	Boost Target	Market Perform	$166.00 ➝ $192.00	Low
8/4/2022	Morgan Stanley	Boost Target	Equal Weight	$159.00 ➝ $225.00	N/A
8/4/2022	Chardan Capital	Boost Target	Buy	$200.00 ➝ $250.00	Low
8/4/2022	Needham & Company LLC	Boost Target	Buy	$205.00 ➝ $240.00	Low
8/4/2022	Citigroup	Boost Target		$206.00 ➝ $280.00	Low
7/29/2022	Morgan Stanley	Lower Target	Equal Weight	$164.00 ➝ $159.00	Low
7/29/2022	Citigroup	Lower Target		$211.00 ➝ $206.00	Low
7/15/2022	Morgan Stanley	Lower Target	Equal Weight	$170.00 ➝ $164.00	Low
7/12/2022	Cantor Fitzgerald	Initiated Coverage	Neutral	$175.00	N/A
6/27/2022	Guggenheim	Downgrade	Buy ➝ Neutral		Low
6/16/2022	Needham & Company LLC	Initiated Coverage	Buy	$205.00	High
6/15/2022	SVB Leerink	Boost Target	Market Perform	$96.00 ➝ $98.00	High
6/7/2022	William Blair	Initiated Coverage	Outperform		Medium
5/2/2022	HC Wainwright	Boost Target		$400.00 ➝ $430.00	Medium
4/29/2022	Citigroup	Lower Target		$223.00 ➝ $211.00	High
4/25/2022	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$210.00 ➝ $178.00	Medium
4/12/2022	HC Wainwright	Boost Target	Buy	$350.00 ➝ $400.00	Medium
4/6/2022	Oppenheimer	Reiterated Rating	Outperform	$205.00	Low
3/24/2022	Stifel Nicolaus	Reiterated Rating	Buy	$215.00	Low
2/28/2022	Citigroup	Initiated Coverage	Buy	$223.00	High
2/23/2022	Morgan Stanley	Lower Target	Overweight	$215.00 ➝ $210.00	Low
2/11/2022	Chardan Capital	Reiterated Rating	Buy	$200.00	Medium
2/11/2022	SVB Leerink	Lower Target	Market Perform	$109.00 ➝ $103.00	Medium
2/3/2022	Guggenheim	Upgrade	Neutral ➝ Buy	$170.00	Low
1/28/2022	SVB Leerink	Boost Target	Market Perform	$108.00 ➝ $109.00	High
1/20/2022	HC Wainwright	Boost Target	Buy	$250.00 ➝ $350.00	High
1/18/2022	Morgan Stanley	Lower Target	Overweight	$226.00 ➝ $215.00	High
1/3/2022	Bank of America	Reiterated Rating	Buy ➝ Buy	$211.00	Medium
1/3/2022	Piper Sandler	Upgrade	Neutral ➝ Overweight	$181.00 ➝ $208.00	Low
12/30/2021	Oppenheimer	Reiterated Rating	Outperform	$200.00	Low
12/1/2021	SVB Leerink	Reiterated Rating	Hold		Medium
11/22/2021	Needham & Company LLC	Boost Target	Buy	$180.00 ➝ $205.00	High
11/22/2021	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$273.00	High
11/22/2021	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$144.00 ➝ $225.00	High
11/1/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$200.00	Low
10/31/2021	BMO Capital Markets	Reiterated Rating	Hold ➝ Neutral		Medium
10/29/2021	Morgan Stanley	Lower Target	Overweight	$242.00 ➝ $226.00	High
10/29/2021	Chardan Capital	Boost Target	Buy	$190.00 ➝ $200.00	High
10/29/2021	Cantor Fitzgerald	Boost Target	Overweight	$202.00 ➝ $275.00	Low
10/28/2021	SVB Leerink	Boost Target	Market Perform	$104.00 ➝ $108.00	High
10/18/2021	SVB Leerink	Reiterated Rating	Market Perform		Low
10/12/2021	Morgan Stanley	Boost Target	Overweight	$234.00 ➝ $242.00	Low
10/4/2021	UBS Group	Upgrade	Neutral ➝ Buy	$141.00 ➝ $215.00	Low
8/27/2021	BMO Capital Markets	Boost Target	Neutral ➝ Market Perform	$174.00 ➝ $196.00	Medium
8/13/2021	HC Wainwright	Boost Target	Buy	$235.00 ➝ $250.00	High
8/4/2021	Chardan Capital	Reiterated Rating	Buy	$190.00	Medium
8/4/2021	Morgan Stanley	Boost Target	Overweight	$224.00 ➝ $234.00	High
8/4/2021	Barclays	Boost Target	Overweight	$196.00 ➝ $216.00	High
8/4/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$45.00 ➝ $47.00	High
7/16/2021	Morgan Stanley	Boost Target	Overweight	$205.00 ➝ $224.00	High
4/30/2021	Morgan Stanley	Lower Target	Overweight	$206.00 ➝ $205.00	Low
4/20/2021	Needham & Company LLC	Reiterated Rating	Buy		Low
3/1/2021	Guggenheim	Reiterated Rating	Buy ➝ Neutral	$162.00	Low
2/22/2021	Guggenheim	Downgrade	Buy ➝ Neutral	$162.00	Medium
2/14/2021	Royal Bank of Canada	Reiterated Rating	Hold		Low
2/12/2021	Needham & Company LLC	Boost Target	Buy	$160.00 ➝ $180.00	Low
2/12/2021	Morgan Stanley	Boost Target	Overweight	$203.00 ➝ $206.00	Low
2/12/2021	Citigroup	Downgrade	Buy ➝ Neutral	$170.00 ➝ $175.00	Low
2/12/2021	Barclays	Boost Target	Overweight	$162.00 ➝ $196.00	Low
2/12/2021	HC Wainwright	Boost Target	Buy	$225.00 ➝ $235.00	Low
1/25/2021	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$185.00 ➝ $185.00	High
1/13/2021	Cowen	Boost Target	In-Line ➝ Outperform	$154.00 ➝ $197.00	High
1/8/2021	HC Wainwright	Reiterated Rating	Buy	$225.00	High
12/21/2020	Royal Bank of Canada	Lower Target	Sector Perform	$150.00 ➝ $144.00	Medium
12/17/2020	Piper Sandler	Boost Target	Overweight	$169.00 ➝ $181.00	Low
11/25/2020	BMO Capital Markets	Boost Target		$182.00 ➝ $183.00	Low
11/25/2020	Morgan Stanley	Boost Target	Overweight	$200.00 ➝ $203.00	Low
11/24/2020	SVB Leerink	Boost Target	Market Perform	$90.00 ➝ $91.00	Low
11/6/2020	Morgan Stanley	Boost Target	Overweight	$197.00 ➝ $200.00	High
10/15/2020	Bank of America	Lower Target	Buy	$160.00 ➝ $157.00	Low
10/12/2020	Chardan Capital	Reiterated Rating	Buy		Low
9/30/2020	Oppenheimer	Reiterated Rating	Hold	$156.00	Medium
9/30/2020	Berenberg Bank	Initiated Coverage	Hold	$145.00	Medium
9/8/2020	Citigroup	Initiated Coverage	Buy	$170.00 ➝ $170.00	Low
8/24/2020	HC Wainwright	Reiterated Rating	Buy		Low
8/11/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $156.00	Low
8/7/2020	Morgan Stanley	Lower Target	Overweight	$199.00 ➝ $197.00	Low
8/7/2020	Chardan Capital	Reiterated Rating	Buy		Low
8/7/2020	SVB Leerink	Boost Target	Market Perform	$89.00 ➝ $90.00	Low
7/20/2020	BMO Capital Markets	Boost Target	Outperform	$173.00 ➝ $196.00	High
7/15/2020	Morgan Stanley	Boost Target	Overweight	$162.00 ➝ $199.00	Low
5/28/2020	UBS Group	Boost Target	Neutral	$111.00 ➝ $122.00	Low
5/12/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$150.00	Medium
5/7/2020	BMO Capital Markets	Boost Target	Outperform	$145.00 ➝ $171.00	Low
5/7/2020	Oppenheimer	Boost Target	Outperform	$140.00 ➝ $162.00	High
5/7/2020	Morgan Stanley	Boost Target	Overweight	$148.00 ➝ $162.00	High
5/7/2020	Barclays	Boost Target	Overweight	$143.00 ➝ $156.00	High
5/7/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$133.00 ➝ $137.00	High
5/6/2020	Needham & Company LLC	Boost Target	Buy	$135.00 ➝ $160.00	High
4/24/2020	Evercore ISI	Initiated Coverage	Buy	$160.00	Low
4/14/2020	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High
4/14/2020	Cantor Fitzgerald	Boost Target		$195.00 ➝ $202.00	Low
4/14/2020	Piper Sandler	Lower Target		$147.00 ➝ $142.00	Medium
4/14/2020	Nomura Securities	Lower Target	Reduce	$75.00 ➝ $74.00	Medium
4/13/2020	Oppenheimer	Reiterated Rating	Buy	$140.00	Medium
3/19/2020	Berenberg Bank	Initiated Coverage	Buy	$200.00	Low
3/5/2020	Cowen	Reiterated Rating	Buy		Medium
3/3/2020	Piper Sandler	Reiterated Rating	Buy	$155.00	N/A
2/11/2020	Nomura Securities	Boost Target	Reduce	$62.00 ➝ $75.00	Medium
2/9/2020	Cowen	Reiterated Rating	Buy	$154.00	High
2/7/2020	Evercore ISI	Initiated Coverage	Buy	$145.00	High
2/7/2020	Morgan Stanley	Lower Target	Overweight	$150.00 ➝ $148.00	Medium
2/7/2020	Chardan Capital	Reiterated Rating	Buy		High
2/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High
12/19/2019	Chardan Capital	Boost Target	Buy	$150.00 ➝ $190.00	Low
12/18/2019	Nomura Securities	Reiterated Rating	Sell	$62.00	Low
12/18/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$159.00 ➝ $176.00	Medium
12/17/2019	Piper Jaffray Companies	Boost Target	Overweight	$145.00 ➝ $155.00	Medium
12/17/2019	Morgan Stanley	Boost Target	Overweight	$141.00 ➝ $150.00	High
11/27/2019	Cantor Fitzgerald	Boost Target		$150.00 ➝ $159.00	Low
11/21/2019	BMO Capital Markets	Boost Target	Outperform	$128.00 ➝ $138.00	High
11/21/2019	Barclays	Boost Target	Overweight	$125.00 ➝ $131.00	High
11/21/2019	Needham & Company LLC	Initiated Coverage	Buy	$135.00	Low
11/21/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$150.00 ➝ $159.00	Low
11/19/2019	Oppenheimer	Initiated Coverage	Outperform	$128.00 ➝ $128.00	High
11/18/2019	Cowen	Reiterated Rating	Buy	$120.00	High
11/13/2019	Bank of America	Initiated Coverage	Buy	$110.00	Low
10/31/2019	Needham & Company LLC	Reiterated Rating	Buy	$135.00	Low
10/8/2019	Nomura Securities	Set Target	Sell	$62.00	Low
9/10/2019	Piper Jaffray Companies	Set Target	Buy	$145.00	High
9/4/2019	UBS Group	Boost Target	Neutral	$95.00 ➝ $96.00	Low
9/3/2019	Stifel Nicolaus	Set Target	Buy	$116.00	Low
9/3/2019	Piper Jaffray Companies	Boost Target	Overweight	$142.00 ➝ $145.00	Medium
8/26/2019	Piper Jaffray Companies	Set Target	Buy	$142.00	Low
8/7/2019	Barclays	Reiterated Rating	Buy	$125.00	High
8/7/2019	Morgan Stanley	Lower Target	Overweight	$126.00 ➝ $124.00	High
8/7/2019	Cowen	Lower Target	Outperform	$147.00 ➝ $120.00	High
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$80.00	Medium
5/2/2019	Morgan Stanley	Set Target	Buy	$126.00	High
5/2/2019	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$126.00 ➝ $128.00	High
4/15/2019	Stifel Nicolaus	Boost Target	Buy ➝ Buy	$110.00 ➝ $116.00	Low
4/15/2019	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$135.00 ➝ $138.00	Low
4/15/2019	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$119.00 ➝ $126.00	Low
4/11/2019	Evercore ISI	Initiated Coverage	Outperform	$120.00	Medium
4/9/2019	SVB Leerink	Boost Target	Market Perform	$90.00	Medium
4/9/2019	BMO Capital Markets	Boost Target	Outperform ➝ Outperform	$106.00 ➝ $119.00	High
4/9/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	Medium
4/9/2019	Chardan Capital	Reiterated Rating	Buy	$150.00	Medium
3/6/2019	Cowen	Reiterated Rating	Buy		Low
3/6/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
3/5/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$122.00	Low
2/8/2019	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High
2/8/2019	BMO Capital Markets	Lower Target	Outperform	$106.00	High
2/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	High
1/23/2019	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$87.00	Low
1/15/2019	Piper Jaffray Companies	Lower Target	Overweight	$152.00	Low
12/17/2018	Guggenheim	Initiated Coverage	Buy	$105.00	Medium
12/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	High
11/27/2018	SVB Leerink	Initiated Coverage	Market Perform	$63.00	Low
11/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
10/18/2018	BMO Capital Markets	Reiterated Rating	Buy		High
10/16/2018	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$125.00 ➝ $124.00	Medium
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$135.00	Low
9/28/2018	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $87.00	High

(Data available from 9/21/2018 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

14 very positive mentions
17 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/23/2023

19 very positive mentions
25 positive mentions
3 negative mentions
1 very negative mentions

Mentions as of

3/25/2023

10 very positive mentions
28 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/24/2023

19 very positive mentions
27 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

5/24/2023

12 very positive mentions
11 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

6/23/2023

17 very positive mentions
15 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

7/23/2023

14 very positive mentions
23 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/22/2023

17 very positive mentions
31 positive mentions
2 negative mentions
2 very negative mentions

Mentions as of

9/21/2023

Current Sentiment

Recent Stories by Sentiment

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $173.85

$171.11

$175.39

50 Day Range

MA: $192.99

$175.52

$211.65

52 Week Range

Now: $173.85

$171.08

$242.97

Volume

685,045 shs

Average Volume

685,494 shs

Market Capitalization

$21.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?: The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., EF Hutton Acquisition Co. I, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, StockNews.com, Sumitomo Mitsui Financial Group, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for ALNY.
What is the current price target for Alnylam Pharmaceuticals?: 20 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $247.40, suggesting a possible upside of 41.0%. HC Wainwright has the highest price target set, predicting ALNY will reach $405.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $143.00 for Alnylam Pharmaceuticals in the next year.
View the latest price targets for ALNY.
What is the current consensus analyst rating for Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals currently has 5 hold ratings and 16 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ALNY.
What other companies compete with Alnylam Pharmaceuticals?: Other companies that are similar to Alnylam Pharmaceuticals include United Therapeutics, Ionis Pharmaceuticals, BeiGene, Genmab A/S and Horizon Therapeutics Public. Learn More about companies similar to Alnylam Pharmaceuticals.
How do I contact Alnylam Pharmaceuticals' investor relations team?: Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 551-8200 and its investor relations email address is [email protected]. The official website for Alnylam Pharmaceuticals is www.alnylam.com. Learn More about contacing Alnylam Pharmaceuticals investor relations.

Alnylam Pharmaceuticals - ALNY Stock Price Target and Predictions

Analyst Price Target for ALNY

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.54 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

What is the current price target for Alnylam Pharmaceuticals?

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

What other companies compete with Alnylam Pharmaceuticals?

How do I contact Alnylam Pharmaceuticals' investor relations team?